Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis

Margarida Gonçalves; Linda Tillack; Mamede de Carvalho; Susana Pinto; Harald S. Conradt; Júlia Costa

doi:10.1016/j.cca.2014.09.011

Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis

Margarida Gonçalves, Linda Tillack, Mamede de Carvalho, Susana Pinto, Harald S. Conradt, Júlia Costa

Instituto de Tecnologia Química e Biológica António Xavier (ITQB)

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor neuron for which no clinically validated biomarkers have been identified. Methods: We have quantified by ELISA the biomarker phosphoneurofilament heavy chain (pNFH) in the cerebrospinal fluid (CSF) of ALS patients (n. =. 29) and age-matched control patients with other diseases (n. =. 19) by ELISA. Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. Results: pNFH levels were significantly higher in ALS patients in comparison with controls (P.

Original language	English
Pages (from-to)	342-349
Number of pages	8
Journal	Clinica chimica acta; international journal of clinical chemistry
Volume	438
DOIs	https://doi.org/10.1016/j.cca.2014.09.011
Publication status	Published - 1 Jan 2015

Keywords

Amyotrophic lateral sclerosis
Biomarker
Cerebrospinal fluid
Glycomics
Glycoproteins
Phosphoneurofilament heavy chain

Access to Document

10.1016/j.cca.2014.09.011

Cite this

@article{729c17586b5c41b39887a458edbf566c,

title = "Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis",

abstract = "Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor neuron for which no clinically validated biomarkers have been identified. Methods: We have quantified by ELISA the biomarker phosphoneurofilament heavy chain (pNFH) in the cerebrospinal fluid (CSF) of ALS patients (n. =. 29) and age-matched control patients with other diseases (n. =. 19) by ELISA. Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. Results: pNFH levels were significantly higher in ALS patients in comparison with controls (P. ",

keywords = "Amyotrophic lateral sclerosis, Biomarker, Cerebrospinal fluid, Glycomics, Glycoproteins, Phosphoneurofilament heavy chain",

author = "Margarida Gon{\c c}alves and Linda Tillack and {de Carvalho}, Mamede and Susana Pinto and Conradt, {Harald S.} and J{\'u}lia Costa",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.cca.2014.09.011",

language = "English",

volume = "438",

pages = "342--349",

journal = "Clinica chimica acta; international journal of clinical chemistry",

issn = "0009-8981",

publisher = "Elsevier Science Publisher B.V.",

}

Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis. / Gonçalves, Margarida; Tillack, Linda; de Carvalho, Mamede; Pinto, Susana; Conradt, Harald S.; Costa, Júlia.

In: Clinica chimica acta; international journal of clinical chemistry, Vol. 438, 01.01.2015, p. 342-349.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis

AU - Gonçalves, Margarida

AU - Tillack, Linda

AU - de Carvalho, Mamede

AU - Pinto, Susana

AU - Conradt, Harald S.

AU - Costa, Júlia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor neuron for which no clinically validated biomarkers have been identified. Methods: We have quantified by ELISA the biomarker phosphoneurofilament heavy chain (pNFH) in the cerebrospinal fluid (CSF) of ALS patients (n. =. 29) and age-matched control patients with other diseases (n. =. 19) by ELISA. Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. Results: pNFH levels were significantly higher in ALS patients in comparison with controls (P.

AB - Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor neuron for which no clinically validated biomarkers have been identified. Methods: We have quantified by ELISA the biomarker phosphoneurofilament heavy chain (pNFH) in the cerebrospinal fluid (CSF) of ALS patients (n. =. 29) and age-matched control patients with other diseases (n. =. 19) by ELISA. Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. Results: pNFH levels were significantly higher in ALS patients in comparison with controls (P.

KW - Amyotrophic lateral sclerosis

KW - Biomarker

KW - Cerebrospinal fluid

KW - Glycomics

KW - Glycoproteins

KW - Phosphoneurofilament heavy chain

UR - http://www.scopus.com/inward/record.url?scp=84908125781&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.09.011

DO - 10.1016/j.cca.2014.09.011

M3 - Article

C2 - 25261856

AN - SCOPUS:84908125781

VL - 438

SP - 342

EP - 349

JO - Clinica chimica acta; international journal of clinical chemistry

JF - Clinica chimica acta; international journal of clinical chemistry

SN - 0009-8981

ER -

Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this